ARTICLE | Clinical News
Cosentyx secukinumab regulatory update
November 24, 2014 8:00 AM UTC
EMA’s CHMP recommended approval of Cosentyx secukinumab from Novartis as first-line treatment of moderate to severe plaque psoriasis in adults. Last month, an FDA advisory committee voted unanimously ...